Edition:
United Kingdom

Aeterna Zentaris Inc (AEZS.OQ)

AEZS.OQ on NASDAQ Stock Exchange Capital Market

2.21USD
4:25pm GMT
Change (% chg)

$-0.01 (-0.45%)
Prev Close
$2.22
Open
$2.23
Day's High
$2.23
Day's Low
$2.16
Volume
17,846
Avg. Vol
67,494
52-wk High
$4.25
52-wk Low
$0.78

Latest Key Developments (Source: Significant Developments)

Aeterna Zentaris Announces Departure Of Interim Chief Financial Officer
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS ANNOUNCES DEPARTURE OF INTERIM CHIEF FINANCIAL OFFICER.AETERNA ZENTARIS INC - DEPARTURE OF COMPANY'S INTERIM CHIEF FINANCIAL OFFICER, JEFFREY WHITNELL, EFFECTIVE DECEMBER 7, 2017.AETERNA ZENTARIS INC - COMMENCED A SEARCH FOR WHITNELL'S REPLACEMENT AS PRINCIPAL FINANCIAL OFFICER.  Full Article

Aeterna Zentaris’ MAA for Macrilen™ accepted by EMA
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS’ MARKETING AUTHORIZATION APPLICATION FOR MACRILEN™ (MACIMORELIN) FOR EVALUATION OF ADULT GROWTH HORMONE DEFICIENCY ACCEPTED BY EUROPEAN MEDICINES AGENCY.AETERNA ZENTARIS INC - ‍MAA FOR USE OF MACRILEN FOR EVALUATION OF ADULT GROWTH HORMONE DEFICIENCY BEEN ACCEPTED BY EMA FOR REGULATORY REVIEW​.  Full Article

Aeterna Zentaris reports Q3 loss per share of $0.61
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Aeterna Zentaris Inc :Aeterna Zentaris reports third quarter 2017 financial and operating results.Q3 loss per share $0.61.  Full Article

Aeterna Zentaris to pursue FDA registration of Macrilen
Monday, 13 Feb 2017 

Aeterna Zentaris Inc : Aeterna Zentaris announces plans to pursue FDA registration of Macrilen(tm) . FDA has agreed to consider company's conclusions during a type a meeting . Co concluded that macrilen demonstrated performance supportive of achieving registration with U.S. Food and drug administration . Aeterna Zentaris says co-primary endpoint "negative agreement" with itt, which is considered as more relevant endpoint, was met .Says co-primary endpoint "positive agreement" with itt was not met.  Full Article

Aeterna and Specialised Therapeutics Asia sign exclusive license agreement
Wednesday, 12 Oct 2016 

Aeterna Zentaris Inc : Aeterna Zentaris and Specialised Therapeutics Asia sign exclusive license agreement for the potential marketing of Zoptrex(TM) in Australia and New Zealand . Aeterna Zentaris Inc - company expects to complete phase 3 clinical trial for Zoptrex in 2016 . Aeterna Zentaris Inc - plans to submit a new drug application for Zoptrex(TM) to United States Food And Drug Administration (FDA) in first half of 2017 . Aeterna Zentaris - co to be entitled to receive non-refundable upfront payment in consideration for license to sta of co's IP related to Zoptrex(TM) . Aeterna Zentaris - entitled to non-refundable upfront payment in consideration allso for grant to STA of right to commercialize Zoptrex in territory . Aeterna Zentaris - STA has also agreed to make additional payments to co upon achieving certain pre-established regulatory and commercial milestones . Aeterna zentaris- STA has also agreed to make additional payments to co such as double-digit royalties on future net sales of Zoptrex(TM) in territory . Aeterna Zentaris - STA will be responsible for development, reimbursement, commercialization of product in territory (Australia, New Zealand) .Aeterna Zentaris Inc - supply agreement with STA pursuant to which company will supply zoptrex(TM) to sta for duration of license agreement.  Full Article

Aeterna Zentaris reports Q2 loss per share $0.71
Tuesday, 9 Aug 2016 

Aeterna Zentaris Inc : Aeterna Zentaris reports second quarter 2016 financial and operating results . Q2 loss per share $0.71 .Product development programs on track towards FDA submission in 2017.  Full Article

Aeterna and Rafa Laboratories sign license agreement for Zoptrex in Israel
Monday, 1 Aug 2016 

Aeterna Zentaris Inc : Aeterna Zentaris and Rafa Laboratories sign exclusive license agreement for Zoptrex in Israel . Company expects to complete phase 3 clinical trial in Q3 of 2016 . Company and Rafa have also entered into a supply agreement . Entitled to receive a non-refundable upfront payment in consideration for license to Rafa of intellectual property related to Zoptrex .Company will supply Zoptrex to Rafa for duration of license agreement.  Full Article

Aeterna Zentaris, Orient Europharma sign license agreement for Zoptrex
Friday, 1 Jul 2016 

Aeterna Zentaris Inc : Aeterna Zentaris and Orient Europharma Co Ltd sign exclusive license agreement for Zoptrex in Taiwan and Southeast Asia . Co will be entitled to receive non-refundable upfront payment for license to Cyntec of co's intellectual property related to Zoptrex . Company expects to complete Phase 3 clinical trial in Q3 of 2016 for Zoptrex . Cyntec agreed to make additional payments to co upon achieving certain pre-established regulatory and commercial milestones .Company will receive royalties on future net sales of Zoptrex in Taiwan, 9 countries in Southeast Asia.  Full Article

Aeterna Zentaris says IND submission by Sinopharm A-Think
Tuesday, 14 Jun 2016 

Aeterna Zentaris Inc : Aeterna Zentaris announces IND submission by Sinopharm A-Think .Sinopharm A-Think pharmaceuticals co submitted IND for Zoptrex to Chinese state food and drug administration.  Full Article

Aeterna zentaris to file a NDA for zoptrex in first half of 2017
Monday, 6 Jun 2016 

Aeterna Zentaris Inc : Aeterna Zentaris reconfirms commitment to LHRH-receptor targeting zoptrex during 2016 ASCO annual meeting . Phase III trial for endometrial cancer expected to be completed in Q3 2016 .To file a new drug application for zoptrex in first half of 2017.  Full Article